Coronary Artery Disease and Myocardial Infarction

Thomas R Gilpin , Annette Maznyczka , Brijesh Anantharam , et al

Read time: 18m

Bernhard Haring , Michael Böhm ,

Read time: 18m

Vikas Kadiyala , Khung Keong Yeo ,

Read time: 18m
ACC.24: The ORBITA COSMIC Trial

Rasha Al-Lamee, Michael Foley,

Watch time: 4m 45s

Samshol Sukahri , Ahmad Syadi Mahmood Zuhdi , Kok Han Chee , et al

Read time: 18m 10s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s
ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s

Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al

Read time: 18m 10s

Gabriel Torres-Ruiz , Nuria Mallofré-Vila , Paola Rojas-Flores , et al

Read time: 18m

Giulia Botti , Sharmaine Thirunavukarasu , Francesca Ziviello , et al

Read time: 18m

Xian Wen Tan , Alan Yean Yip Fong , Siaw San Hwang ,

Read time: 18m

Billy Joseph David , Reynald Evan Tugade , Ferdinand Jr Gerodias ,

Read time: 18m

Jean-Claude Tardif,

Watch time: 1h 4m 5s (13 videos)

Heather Currie , Christine Williams ,

Read time: 10m

Edward T Carreras , Donna M Polk ,

Tullio Palmerini , Carlo Savini , Marco Di Eusanio ,

Read time: 18m

Sivabaskari Pasupathy , Rosanna Tavella , Simon McRae , et al

Remo Albiero ,

Hans-Willi Breuer ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Astrid Hubert , Andreas Seitz , Valeria Martínez Pereyra , et al

Kamal Chitkara , Anthony H Gershlick ,

Media

AHA 23: Preventive Cardiology in 2023

Michael Honigberg,

Watch time: 7m 3s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23 Late-Breaker Discussion: The RECORD MI Registry

Harriette Van Spall, Javed Butler,

Watch time: 9m 37s
ESC 23: The ILUMIEN IV Trial

Ziad A Ali,

Watch time: 4m 12s

Yugo Yamashita,

Shigeru Saito, Stefan Verheye,

Watch time: 12m 53s (2 videos)

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)

Lale Tokgözoğlu, Kausik Ray, Ulrich Laufs, et al

Watch time: 1h 23m 3s (5 videos)

Sandeep Nathan, Dan Burkhoff, Jerry D Estep, et al

Watch time: 1h 31s
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s

Media

ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s
ACC.24: The ORBITA COSMIC Trial

Rasha Al-Lamee, Michael Foley,

Watch time: 4m 45s
Cardiovascular Outcomes For People Using Anticoagulation Strategies At ESC 2017 discuss with Professor Eugene Braunwald

Eugene Braunwald, Afzal Sohaib,

Watch time: 8m 50s
CRT 23: PCI Vs CABG in Left Main CAD With or Without Diabetes: A Pooled Ana

Prakriti Gaba,

Watch time: 4m 19s

José M de la Torre Hernández, Lucio Padilla, Adam Sukiennik, et al

Watch time: 6m 37s (7 videos)
ESC 2019 - Changes to ESC Guidelines for High-Risk Pulmonary Embolism Patients

Nicolas Meneveau,

Watch time: 1m 19s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
Coronary Physiology Round Table: Coronary Physiology in the Real World

Simon Kennon,

Watch time: 26m 2s
ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

R Scott Wright,

Watch time: 13m 43s
ACC 2020: Primary Results of the Voyager PAD Trial

Marc P Bonaca,

Watch time: 7m 9s
ACC 2020 Wrap Up: An Analysis of the Late-breaking Trials

Joost Daemen, Nicolas M Van Mieghem,

Watch time: 31m 31s

Articles

Adherence to Lipid Lowering—Growing Clinical Challenge

JoAnne M Foody

,

Citation:

US Cardiology 2006;3(2):24–7

DOI:

https://doi.org/10.15420/usc.2006.3.2.24
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 466
  • Downloads: Downloads 1

Hypertension and Diabetes Mellitus

Gurushankar Govindarajan

,

James R Sowers

,

Craig S Stump

,

Citation:

European Cardiovascular Disease 2006;2(1):21–4

DOI:

https://doi.org/10.15420/ecr.2006.1.21
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 1315
  • Downloads: Downloads 8
  • Citations: 4

NT-BNP in Stable Coronary Artery Disease

Venu Menon

,

Citation:

European Cardiovascular Disease 2006;2(2):1–4

DOI:

https://doi.org/10.15420/ecr.2006.0.2.1j
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 463
  • Downloads: Downloads 2

CTA and MPI—A Comparison in Detecting Significant Coronary Artery Disease

Matthew J Budoff

,

Ambarish Gopal

,

Citation:

US Cardiology 2006;3(2):1–6

Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2392
  • Downloads: Downloads 9